Clinical trials: PD-1 Inhibitors
HCC, Recurrence
VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06253364
- Testing
- PD-1 monoclonal antibody and lenvatinib
- Where
- China
- Volunteers
- 462 people
- Sponsor
- Chen Xiaoping
Opportunistic Autoimmune Diseases
Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
This is a real life observational longitudinal study aiming to identify autoimmune manifestations in patients treated with "checkpoint inhibitors" in mono or combo therapy in real life.
- Trial name
- PRAISE (NCT03849131)
- Testing
- Biological collection
- Where
- France
- Volunteers
- 905 people
- Sponsor
- University Hospital, Strasbourg, France
Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)…
- Conditions
- Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT07392073
- Testing
- Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Objective Response Rate
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
This is an intervention study, aiming to use high and low dose radiotherapy combined with PD-1/PD-L1 inhibitor combined with GM-CSF to observe the effect of anti-tumor immunity and long-term therapeutic response rate, and to…
- Trial name
- NCT05760196
- Testing
- GM-CSF
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Xiangpan Li
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable…
- Trial name
- REVO (NCT05007145)
- Testing
- PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 92 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by…
- Trial name
- Keynote-559 (NCT03168139)
- Testing
- Olaptesed pegol - Monotherapy, Olaptesed pegol + Pembrolizumab - Combination Therapy
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- TME Pharma AG
Locally Advanced Rectal Cancer (LARC)
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant…
- Trial name
- NCT06933251
- Testing
- Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Squamous Cell Carcinoma of Head and Neck
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic).
- Trial name
- NCT04428151
- Testing
- Lenvatinib, Pembrolizumab, Docetaxel
- Where
- 120 sites in United States, Australia and 13 more
- Volunteers
- 408 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups.
- Trial name
- NCT07559045
- Testing
- Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Advanced Solid Tumor
Study of AGEN1571 in Participants With Advanced Solid Tumors
This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination…
- Trial name
- NCT05377528
- Testing
- AGEN1571, Balstilimab, Botensilimab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Agenus Inc.
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
Recurrent Rectal Cancer
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, phase II clinical trial. Patients with pelvic recurrent rectal cancer aged from 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0-1, will receive…
- Trial name
- TRACER (NCT06751394)
- Testing
- PD-1 antibody (Toripalimab), Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Treatment Efficacy
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
A number of anti-PD-1/L1 monoclonal antibodies have been approved for the treatment of various advanced tumors in the world, and many studies on anti-PD-1 /L1 monoclonal antibodies for breast cancer are also being carried out.
- Trial name
- CHANGEABLE (NCT04508803)
- Testing
- HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Radiotherapy, Metastatic Solid Cancers
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Preclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors…
- Conditions
- Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
- Trial name
- ILDR-02 (NCT07071103)
- Testing
- Low-dose radiotherapy to the intestine (ILDR), PD-1/PD-L1 monoclonal antibodies
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chuangzhen Chen
Myocarditis, Cardiac Complication
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) on the cardio-vascular system. This study investigates reports of cardio-vascular toxicity with treatment including anti-PD1…
- Trial name
- RAFALE (NCT03387540)
- Testing
- ICI
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
- Trial name
- NCT03946943
- Testing
- Anlotinib, Toripalimab, Blood Draw
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Di Wu